Neurogene Inc.

What they do

Neurogene uses its proprietary EXACT (Expression Attenuation via Construct Tuning) transgene regulation technology, which employs microRNA-based genetic circuits, together with adeno-associated virus (AAV) delivery via intracerebroventricular (ICV) administration. Its lead program, NGN-401, delivers the full-length MECP2 gene and is in a registrational trial called Embolden for females with Rett syndrome. Clinical-grade NGN-401 is manufactured at the company's cGMP facility in Houston, Texas. The company also conducts preclinical research, including through a collaboration with the University of Edinburgh.

Revenue drivers

• Product revenue — Neurogene has no products approved for commercial sale and has never generated product revenue.
• Collaboration or grant revenue — Annual revenue was $0.00 in 2023, $925,000 in 2024 and $0.00 in 2025, with $0.00 reported in the quarters ended 2025-06-30 and 2025-09-30.
• NGN-401 (Rett syndrome) — The lead program is in a registrational trial but is not approved or marketed, so it generates no revenue today.

Recent performance

Neurogene reported no revenue in 2025, compared with $925,000 in 2024, and quarterly revenue was $0.00 in the quarters ended 2025-06-30 and 2025-09-30. Net loss was $90.4 million in 2025 versus $75.1 million in 2024, and operating cash flow was negative $77.2 million in 2025 versus negative $70.6 million in 2024. As of December 31, 2025, the company had an accumulated deficit of $352.6 million and cash, cash equivalents and short-term investments of $269.0 million. As of June 30, 2026, total assets were $244.4 million, total liabilities $27.2 million, shareholder equity $217.1 million and cash and equivalents $112.5 million. The company states that Embolden has completed dosing of 25 participants, and in June 2026 it announced positive long-term Phase 1/2 data with all 10 participants improving on CGI-I and gaining one or more developmental milestones.

Strategy

Neurogene is focused on advancing NGN-401 through the Embolden registrational trial, a single-arm, open-label, baseline-controlled study evaluating the 1E15 vg dose in females with Rett syndrome, designed to support a broad label in a single study. The company expects top-line Embolden results in the second half of 2027 and is conducting Process Performance Qualification activities for chemistry, manufacturing and controls requirements. It continues to rely on in-house cGMP manufacturing in Houston for product quality, timeline and clinical-to-commercial continuity, and maintains early-stage discovery work, including an academic collaboration with the University of Edinburgh. Since inception, it has funded operations primarily with outside capital and has raised aggregate net proceeds of approximately $552.1 million.

Risks

• Dependence on NGN-401 — The company is substantially dependent on the success of its most advanced product candidate, NGN-401, and its ongoing clinical trial may not be successful.
• Need for substantial additional capital — Management states that it will require substantial additional capital and, if unable to raise it on acceptable terms, may have to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts.
• No approved products or revenue — Neurogene has no products approved for commercial sale, has not generated any product revenue and may never generate product revenue or become profitable.
• Manufacturing execution — Delays in developing manufacturing capabilities or failure to achieve operating efficiencies may require additional resources and management time and may delay product development timelines.

Outlook

Management expects top-line results from the Embolden registrational trial of NGN-401 in the second half of 2027. The company plans to continue PPQ activities for CMC requirements and to supplement the overall safety and durability data set with data from an additional participant. Neurogene expects expenses and capital requirements to increase substantially in connection with ongoing activities, and it plans to fund operations and capital expenditures with cash on hand and the sale and issuance of securities.